HSF1 and prostate carcinoma: Consistent with our published results in human ovarian cancer cells (43), NXP800 (Supplementary Fig. S1A), but not its closely matched inactive chemical control compound CCT365248 (Supplementary Fig. S1B), inhibited the induction of HSP72 protein expression in response to HSF1 activation, mediated by HSP90 inhibition, in a concentration-dependent manner in VCaP, LNCaP95 and 22Rv1 prostate cancer cells (Supplementary Fig. S4A–S4C).